Cancer Quick Takes

This study compared the safety and efficacy of a new regimen—bortezomib plus dexamethasone and vincristine— compared with vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (VAD) in previously untreated multiple myeloma (MM) (J Clin Oncol. 2010;28:4621-4629).
Read Article

A discussion of new drug development using the example of acute myeloid leukemia (AML)—but that is applicable to a broad range of diseases— outlines the problems inherent in phase 2 clinical trials that may lead to falsepositive results, and how trial design can be improved and drug development be made more efficient and less costly (Blood. 2010;116:2420-2428).
Read Article

In patients with multiple myeloma with light chain–induced renal failure, treatment with a combination known as BDD (bortezomib [Velcade], doxorubicin [Adriamycin], and dexamethasone [Decadron]) resulted in a high rate of myeloma and renal responses that was well tolerated by patients (J Clin Oncol. 2010;28:4635-4641).
Read Article